Economic benefits of treating medication-overuse headache - results from the multicenter COMOESTAS project.

Medication-overuse detoxification direct health care costs medication consumption productivity loss

Journal

Cephalalgia : an international journal of headache
ISSN: 1468-2982
Titre abrégé: Cephalalgia
Pays: England
ID NLM: 8200710

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 10 7 2018
medline: 14 4 2020
entrez: 10 7 2018
Statut: ppublish

Résumé

Medication-overuse headache is a costly disease for individuals and society. To estimate the impact of medication-overuse headache treatment on direct and indirect headache-related health care costs. This prospective longitudinal study was part of the COMOESTAS project (COntinuous MOnitoring of Medication Overuse Headache in Europe and Latin America: development and STAndardization of an Alert and decision support System). Patients with medication-overuse headache were included from four European and two Latin American headache centers. Costs of acute medication, costs of health care services, and measurements of productivity were calculated at baseline and at 6-month follow-up Treatment consisted of overused drug withdrawal with optional preventive medication. A total of 475 patients (71%) completed treatment and were followed up for 6 months. Direct health care costs were on average reduced significantly by 52% ( p < 0.001) for the total study population. Significant reductions were seen in both number of consumed tablets (-71%, p < 0.001) and number of visits to physicians (-43%, p < 0.001). Fifty percent of patients reduced their number of consumed tablets ≥ 80%. Headache-related productivity loss, calculated either as absence from work or ≥ 50% reduction of productivity during the workday, were reduced by 21% and 34%, respectively ( p < 0.001). Standardized treatment of medication-overuse headache in six countries significantly reduced direct health care costs and increased productivity. This emphasizes the importance of increasing awareness of the value of treating medication-overuse headache. The trial was registered at ClinicalTrials.gov (no. NCT02435056).

Sections du résumé

BACKGROUND
Medication-overuse headache is a costly disease for individuals and society.
OBJECTIVE
To estimate the impact of medication-overuse headache treatment on direct and indirect headache-related health care costs.
METHODS
This prospective longitudinal study was part of the COMOESTAS project (COntinuous MOnitoring of Medication Overuse Headache in Europe and Latin America: development and STAndardization of an Alert and decision support System). Patients with medication-overuse headache were included from four European and two Latin American headache centers. Costs of acute medication, costs of health care services, and measurements of productivity were calculated at baseline and at 6-month follow-up Treatment consisted of overused drug withdrawal with optional preventive medication.
RESULTS
A total of 475 patients (71%) completed treatment and were followed up for 6 months. Direct health care costs were on average reduced significantly by 52% ( p < 0.001) for the total study population. Significant reductions were seen in both number of consumed tablets (-71%, p < 0.001) and number of visits to physicians (-43%, p < 0.001). Fifty percent of patients reduced their number of consumed tablets ≥ 80%. Headache-related productivity loss, calculated either as absence from work or ≥ 50% reduction of productivity during the workday, were reduced by 21% and 34%, respectively ( p < 0.001).
CONCLUSION
Standardized treatment of medication-overuse headache in six countries significantly reduced direct health care costs and increased productivity. This emphasizes the importance of increasing awareness of the value of treating medication-overuse headache.
TRIAL REGISTRATION
The trial was registered at ClinicalTrials.gov (no. NCT02435056).

Identifiants

pubmed: 29984608
doi: 10.1177/0333102418786265
doi:

Banques de données

ClinicalTrials.gov
['NCT02435056']

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

274-285

Commentaires et corrections

Type : ErratumIn

Auteurs

Pernille Linde Jellestad (PL)

1 Danish Headache Centre, Department of Neurology, Rigshospitalet Glostrup, Glostrup, Denmark.

Louise Ninett Carlsen (LN)

1 Danish Headache Centre, Department of Neurology, Rigshospitalet Glostrup, Glostrup, Denmark.

Maria Lurenda Westergaard (ML)

1 Danish Headache Centre, Department of Neurology, Rigshospitalet Glostrup, Glostrup, Denmark.

Signe Bruun Munksgaard (SB)

1 Danish Headache Centre, Department of Neurology, Rigshospitalet Glostrup, Glostrup, Denmark.

Lars Bendtsen (L)

1 Danish Headache Centre, Department of Neurology, Rigshospitalet Glostrup, Glostrup, Denmark.

Miguel Lainez (M)

2 Department of Neurology, Pontificia Catolica University of Chile, Santiago, Chile.

Ricardo Fadic (R)

3 Foundation of the Valencian Community, University Clinical Hospital, Valencia, Spain.

Zaza Katsarava (Z)

4 Department of Neurology, University of Essen, Essen, Germany.

Maria Teresa Goicochea (MT)

5 Foundation for Combatting Neurological Diseases of Childhood, Buenos Aires, Argentina.

Santiago Spadafora (S)

6 ISalud University, Buenos Aires, Argentina.

Rigmor Højland Jensen (RH)

1 Danish Headache Centre, Department of Neurology, Rigshospitalet Glostrup, Glostrup, Denmark.

Giuseppe Nappi (G)

7 Headache Science Centre, C. Mondino National Neurological Institute, Pavia, Italy.

Cristina Tassorelli (C)

7 Headache Science Centre, C. Mondino National Neurological Institute, Pavia, Italy.
8 Department of Brain and Behavioral Sciences, University of Pavia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH